Hyperbaric oxygen therapy in the management of crush injuries: A randomized double-blind placebo-controlled clinical trial

被引:148
|
作者
Bouachour, G [1 ]
Cronier, P [1 ]
Gouello, JP [1 ]
Toulemonde, JL [1 ]
Talha, A [1 ]
Alquier, P [1 ]
机构
[1] CHU ANGERS,SERV CHIRURG RECONSTRUCT & TRAUMATOL,F-49033 ANGERS 01,FRANCE
关键词
D O I
10.1097/00005373-199608000-00023
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Hyperbaric Oxygen (HBO) therapy is advocated for the treatment of severe trauma of the limbs in association with surgery because of its effects on peripheral oxygen transport, muscular ischemic necrosis, compartment syndrome, and infection prevention, However, no controlled human trial had been performed until now to specify the role of HBO in the management of crush injuries, Thirty-six patients with crush injuries were assigned in a blinded randomized fashion, within 24 hours after surgery, to treatment with HBO (session of 100% O-2 at 2.5 atmosphere absolute (ata) for 90 minutes, twice daily, over 6 days) or placebo (session of 21% O-2 at 1.1 ata for 90 minutes, twice daily, over 6 days), All the patients received the same standard therapies (anticoagulant, antibiotics, wound dressings), Transcutaneous oxygen pressure (PtCO2) measurements were done before (patient breathing normal air) and during treatment (HBO or placebo) at the first, fourth, eighth, and twelfth sessions, The two groups (HBO group, n = 18; placebo group, n = 18) were similar in terms of age; risk factors; number, type or location of vascular injuries, neurologic injuries, or fractures; and type, location, or timing of surgical procedures, Complete healing was obtained for 17 patients in the HBO group vs, 10 patients in the placebo group (p < 0.01), New surgical procedures (such as skin flaps and grafts, vascular surgery, or even amputation) were performed on one patient in the HBO group vs, six patients in the placebo group (p < 0.05), Analysis of groups of patients matched for age and severity of injury showed that in the subgroup of patients older than 40 with grade III soft-tissue injury, wound healing was obtained for seven patients (87.5%) in the HBO group vs, three patients (30%) in the placebo group (p < 0.05), No significant differences were found in the length of hospital stay and number of wound dressings between groups, For the patients with complete healing, the PtCO2 values of the traumatized limb, measured in normal air, rose significantly between the first and the twelfth sessions (p < 0.001). No significant change in PtCO2 value was found for the patients whose healing failed, The Bilateral Perfusion Index (BPI = PtCO2 of the injured limb/PtCO2 of the uninjured limb) at the first session increased significantly from 1 ata air to 2.5 ata O-2 (p < 0.05), In patients with complete healing, the BPI was constantly greater than 0.9 at 2.5 ata O-2 during the following sessions, whereas the BPI in air progressively rose between the first and the twelfth sessions (p < 0.05), reaching normal values at the end of the treatment, In conclusion, this study shows the effectiveness of HBO in improving wound healing and reducing repetitive surgery, We believe that HBO is a useful adjunct in the management of severe (grade III) crush injuries of the limbs in patients more than 40 years old.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [41] Light therapy for bipolar depression: a randomized, double-blind, parallel, placebo-controlled trial
    Sit, D.
    McGowan, J.
    Wiltrout, C.
    Diler, R. S.
    Dills, J.
    Luther, J.
    Seltman, H.
    Wisniewski, S.
    Terman, M.
    Wisner, K. L.
    BIPOLAR DISORDERS, 2017, 19 : 60 - 61
  • [42] SULFASALAZINE THERAPY FOR PSORIATIC-ARTHRITIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    GROBER, JS
    MCCUNE, WJ
    GUPTA, AK
    ELLIS, CN
    SIEGEL, MT
    VOORHEES, JJ
    CLINICAL RESEARCH, 1991, 39 (02): : A309 - A309
  • [43] Filtration leukocytapepheresis therapy in rheumatoid arthritis - A randomized, double-blind, placebo-controlled trial
    Hidaka, T
    Suzuki, K
    Matsuki, Y
    Takamizawa-Matsumoto, M
    Kataharada, K
    Ishizuka, T
    Kawakami, M
    Nakamura, H
    ARTHRITIS AND RHEUMATISM, 1999, 42 (03): : 431 - 437
  • [44] Gabapentin in the Management of Pain following Tonsillectomy: A Randomized Double-Blind Placebo-Controlled Trial
    Sanders, James G.
    Cameron, Claire
    Dawes, Patrick J. D.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 157 (05) : 781 - 790
  • [45] Amantadine therapy for chronic hepatitis CA randomized double-blind placebo-controlled trial
    Jill P. Smith
    Thomas R. Riley
    Attila Devenyi
    Sandra I. Bingaman
    Allen Kunselman
    Journal of General Internal Medicine, 2004, 19 : 662 - 668
  • [46] Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial
    Hari, Pankaj
    Hari, Smriti
    Sinha, Aditi
    Kumar, Rakesh
    Kapil, Arti
    Pandey, Ravindra Mohan
    Bagga, Arvind
    PEDIATRIC NEPHROLOGY, 2015, 30 (03) : 479 - 486
  • [47] Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial
    Rezaei, Farzin
    Ghaderi, Ebrahim
    Mardani, Roya
    Hamidi, Seiran
    Hassanzadeh, Kambiz
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 (03) : 282 - 289
  • [48] Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial
    Pankaj Hari
    Smriti Hari
    Aditi Sinha
    Rakesh Kumar
    Arti Kapil
    Ravindra Mohan Pandey
    Arvind Bagga
    Pediatric Nephrology, 2015, 30 : 479 - 486
  • [49] The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial
    Kuipers, Thijs
    Oude Nijhuis, Renske A. B.
    Schuitenmaker, Jeroen M.
    Bredenoord, Albert J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (10):
  • [50] Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial
    Campillo, Jeremy T.
    Bikita, Paul
    Hemilembolo, Marlhand
    Louya, Frederic
    Missamou, Francois
    Pion, Sebastien D. S.
    Boussinesq, Michel
    Chesnais, CedricB
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : 19 - 27